The Sculptique Aesthetics
Tirzepatide (Mounjaro) Dosage Guide: Complete Weight Loss Protocol for India & Mumbai (2026)
Tirzepatide (Mounjaro) dosage for weight loss — complete escalation schedule, starting dose, maintenance dose, tirzepatide vs semaglutide dose comparison, side effects and medically supervised protocols from The Sculptique Aesthetics Mumbai.
Tirzepatide dosage follows a structured escalation schedule — and because tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity) is a dual-action GIP/GLP-1 agonist, getting that escalation right produces weight loss results that significantly exceed semaglutide in head-to-head data. In the SURMOUNT-1 trial, patients on tirzepatide 15 mg lost an average of 20.9 % of body weight — more than any approved weight-loss drug in history at the time of publication.
If you're searching for tirzepatide dosage, Mounjaro dose for weight loss, tirzepatide starting dose, tirzepatide dose escalation schedule, tirzepatide 5 mg vs 10 mg vs 15 mg, Mounjaro vs Ozempic dose, or tirzepatide side effects by dose, this guide covers every protocol in clinical use. The Sculptique Aesthetics offers medically supervised weight loss including tirzepatide protocols in Mumbai, Bandra, Khar, Andheri, South Mumbai and across India.
Tirzepatide is a prescription medication in India — it requires proper medical assessment and prescription.
What is tirzepatide and how is it different from semaglutide?
Tirzepatide is the world's first dual GIP/GLP-1 receptor agonist — it activates two incretin pathways simultaneously:
- GLP-1 receptor (glucagon-like peptide-1): same pathway as semaglutide — suppresses appetite, slows gastric emptying, reduces glucagon, improves insulin secretion
- GIP receptor (glucose-dependent insulinotropic polypeptide): second pathway — enhances insulin sensitivity in adipose tissue and muscle, reduces fat deposition, and may reduce the GI side effects that limit GLP-1-only drugs
The dual action explains tirzepatide's superior weight loss efficacy compared to semaglutide — both GIP and GLP-1 pathways work together to reduce fat accumulation and appetite more comprehensively than either alone.
For a detailed comparison, see Ozempic vs Mounjaro and semaglutide dosage guide.
Tirzepatide dose escalation schedule
The standard Mounjaro / tirzepatide dose escalation approved for use:
| Week | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5 mg SC once weekly | Starting dose — tolerance building only, not therapeutic for weight loss |
| Weeks 5–8 | 5 mg SC once weekly | First meaningful therapeutic dose for most patients |
| Weeks 9–12 | 7.5 mg SC once weekly | Significant appetite suppression established |
| Weeks 13–16 | 10 mg SC once weekly | Majority of patients see best-tolerated effective dose here |
| Weeks 17–20 | 12.5 mg SC once weekly | Bridge dose |
| Week 21+ | 15 mg SC once weekly | Maximum approved dose — highest efficacy in trials |
Escalation rule: only advance to the next dose if the current dose is well tolerated for the full 4 weeks. If not tolerated, stay at the current dose for an additional 4 weeks before retrying. Never escalate through persistent nausea or vomiting.
Many patients reach their optimal maintenance dose at 10 mg or 12.5 mg rather than 15 mg — the goal is the lowest dose that delivers meaningful, sustained weight loss, not the maximum possible dose.
Tirzepatide weight loss by dose — what the data shows
From the SURMOUNT-1 trial (72 weeks, patients with obesity, no diabetes):
| Dose | Average weight loss | % achieving ≥15 % loss | % achieving ≥20 % loss |
|---|---|---|---|
| 5 mg | ~15 % of body weight | 52 % | 22 % |
| 10 mg | ~19.5 % of body weight | 67 % | 37 % |
| 15 mg | ~20.9 % of body weight | 63 % | 57 % |
| Placebo | ~2.5 % | — | — |
For context: semaglutide 2.4 mg (Wegovy) achieves approximately 12–15 % average body weight loss. Even tirzepatide's lowest therapeutic dose (5 mg) typically exceeds semaglutide's maximum at population level.
Tirzepatide maintenance dose
Maintenance is the lowest dose that sustains meaningful appetite suppression and weight stability after the goal is reached (or progress plateaus):
- Most patients maintain on 5–10 mg weekly once the target weight is approached
- Some patients can step down from 15 mg → 10 mg → 7.5 mg during maintenance without weight regain; this requires careful monitoring
- Stopping tirzepatide typically leads to progressive weight regain over months — long-term use is part of the clinical discussion
Tirzepatide dose for patients who have not responded to semaglutide
For patients who tried Ozempic at 1–2 mg with modest results:
- Begin tirzepatide at 2.5 mg → 5 mg → 7.5 mg per standard escalation
- Most semaglutide partial-responders achieve meaningfully better results on tirzepatide at 10–15 mg
- Do not overlap the two — stop semaglutide before starting tirzepatide; allow 1 week between the last semaglutide dose and first tirzepatide dose (both are weekly injectables with ~7-day half-life)
Injection guide: how to inject tirzepatide correctly
- Route: subcutaneous injection with the pre-filled auto-injector pen (KwikPen for Mounjaro)
- Sites: abdomen (preferred), outer thigh, upper arm — rotate sites each week
- Day: any day of the week, same day each week; food timing irrelevant
- Storage in use: room temperature (below 30 °C) for up to 21 days (Mounjaro); unopened pens refrigerated at 2–8 °C
What to do if you miss a tirzepatide injection
- Missed by less than 4 days (96 hours): inject as soon as you remember
- Missed by more than 4 days: skip and continue on your normal day next week
- Never inject two doses in the same week
Tirzepatide dosage for Type 2 diabetes (Mounjaro indication)
The diabetes-approved escalation differs slightly:
- Start: 2.5 mg once weekly × 4 weeks → 5 mg once weekly
- If additional glycaemic control needed: increase to 7.5 mg → 10 mg → 12.5 mg → 15 mg at 4-week intervals
- HbA1c reduction at 15 mg: approximately 2.1–2.3 % (better than most available diabetes medications)
- Blood glucose monitoring required; adjust other diabetes medications as HbA1c improves to avoid hypoglycaemia
Tirzepatide vs semaglutide dosage comparison
| Semaglutide (Wegovy) | Tirzepatide (Mounjaro) | |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GIP + GLP-1 agonist |
| Starting dose | 0.25 mg | 2.5 mg |
| Maximum dose | 2.4 mg | 15 mg |
| Injection frequency | Once weekly | Once weekly |
| Average weight loss (max dose, 68–72 weeks) | ~12–15 % | ~19–21 % |
| GI side effects | Common | Slightly lower than semaglutide |
| Use for sema non-responders | — | Effective escalation |
For patients who have done Ozempic and want more — tirzepatide is the natural next step.
Tirzepatide side effects by dose
Side effects are dose-dependent and most prominent during the escalation phase. They diminish significantly once the patient has been stable at a dose for 4–6 weeks.
Common (GI — dose-escalation dependent)
- Nausea — most common, particularly weeks 1–3 at each new dose. Manage by: evening injection (sleep through peak side effect window), small meals, avoiding fatty food
- Vomiting — if >2 episodes per week, do not escalate; stay at current dose
- Diarrhoea — common in first 2–4 weeks at new dose; usually resolves
- Constipation — some patients experience this instead; increase water and fibre
- Reduced appetite — desired therapeutic effect; monitor for under-eating and muscle loss (maintain protein ≥1.2 g/kg/day)
- Fatigue — early weeks; resolves
Less common
- Injection site reactions — mild redness, bruising; rotate sites
- GERD / reflux — slowed gastric emptying; small meals, avoid lying down after eating
- Hair loss — telogen effluvium from rapid weight loss; self-resolving; adequate protein intake helps
Rare but serious
- Pancreatitis: severe persistent upper abdominal pain radiating to the back — stop and seek emergency care immediately
- Thyroid C-cell tumours (rodent data only): contraindicated in personal or family history of medullary thyroid carcinoma or MEN2
- Gallbladder disease: increased gallstone risk during rapid weight loss
Tirzepatide contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2
- Severe pancreatitis history
- Pregnancy and breastfeeding
- Severe gastroparesis
Managing tirzepatide side effects — practical guidance
| Side effect | Best management |
|---|---|
| Nausea | Inject in the evening; eat small meals; ginger or peppermint tea; no fatty / fried food |
| Vomiting | Pause escalation; stay at current dose; antiemetic if prescribed |
| Constipation | Water 2+ litres daily; fibre; light walking; osmotic laxative if needed |
| Muscle loss | Resistance training; protein ≥1.2 g/kg/day; consider CJC-1295 / Ipamorelin |
| Hair loss | Maintain protein; zinc; iron; biotin; usually self-resolving at 3–6 months |
| Fatigue | Adequate calories; protein; check iron and thyroid |
Tirzepatide and muscle preservation
A major clinical concern with aggressive weight loss is lean tissue loss. On average, weight loss from GLP-1 / GIP agonists includes approximately 25–40 % lean mass alongside fat — meaning a 20 kg loss might include 5–8 kg of muscle.
At The Sculptique Aesthetics, for patients losing significant weight on tirzepatide we routinely recommend:
- Protein intake: ≥1.5 g/kg/day of current (not target) body weight
- Resistance training: 3+ sessions per week
- CJC-1295 / Ipamorelin: GH peptide protocol alongside tirzepatide to preserve lean tissue and support metabolic rate
- NAD+ IV: addresses the metabolic fatigue and mitochondrial demands of aggressive weight loss
Frequently asked questions
2.5 mg SC once weekly for the first 4 weeks. This is a tolerance-building dose — not a therapeutic weight-loss dose. Progress to 5 mg at week 5.
15 mg once weekly — the maximum approved dose. Associated with approximately 20.9 % average body weight loss at 72 weeks (SURMOUNT-1). Most patients reach effective maintenance at 10–12.5 mg.
Tirzepatide starts at 2.5 mg vs semaglutide's 0.25 mg — the doses are not comparable because the compounds have different pharmacology. Tirzepatide's dual GIP/GLP-1 action produces greater average weight loss than semaglutide at comparable points in the escalation schedule. See Ozempic vs Mounjaro.
Minimum 4 weeks at each dose before escalating. If side effects are problematic, stay 8 weeks at the current dose before trying the next level.
Appetite suppression: noticeable within 1–2 weeks at the 5 mg dose. Weight loss: measurable in 4–8 weeks. Maximum effect at target dose: requires 16–24 weeks to fully establish.
Mounjaro (tirzepatide) availability in India is growing but supply can be inconsistent. At The Sculptique Aesthetics we source appropriately and guide patients on the best available option — including when retatrutide may be an alternative. See retatrutide.
Yes. Tirzepatide and BPC-157, GHK-Cu, CJC-1295 / Ipamorelin, NAD+ IV are commonly combined in our weight-loss and anti-ageing protocols at The Sculptique Aesthetics. There are no known significant interactions — each operates through distinct pathways.
Book your tirzepatide consultation in Mumbai
Tirzepatide is the most effective approved weight-loss medication available based on current trial data. At The Sculptique Aesthetics we approach it as part of a comprehensive plan — combining the medication with dietary support, activity guidance, body composition monitoring and, where appropriate, supporting peptide protocols to preserve muscle and energy.
Contact us to discuss whether tirzepatide, semaglutide or retatrutide is the right protocol for your goals. Serving Mumbai, Bandra, Khar, Andheri, Powai, Juhu, South Mumbai and international patients seeking supervised medical weight loss in India.
